AU2010333656B2 — HCV combination therapy
Assigned to Boehringer Ingelheim International GmbH · Expires 2015-08-27 · 11y expired
What this patent protects
Aspects of this invention include methods comprising administering a combination of a Compound (1) below, including particular en crystalline forms thereof and pharmaceutically acceptable salts thereof, with at least one further selected HCV inhibiting compound as described herei…
USPTO Abstract
Aspects of this invention include methods comprising administering a combination of a Compound (1) below, including particular en crystalline forms thereof and pharmaceutically acceptable salts thereof, with at least one further selected HCV inhibiting compound as described herein for the treatment of Hepatitis C Viral (HCV) infection The methods can be conducted administering the Compound (1) and the at least one further selected HCV inhibiting compound separately or together, including as a regimen of treatment.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.